[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603671":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":55,"collaborators":30,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":30,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":30,"enrollmentInfo":66,"targetDuration":30,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":30,"overallStatus":75,"whyStopped":30,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Guangdong Raynovent Biotech Co., Ltd","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"6mg RAY1225","EXPERIMENTAL","6 milligrams (mg) RAY1225 administered subcutaneously (SC) once every two week.",[13],"Drug: RAY1225",{"label":15,"type":10,"description":16,"interventionNames":17},"9mg RAY1225","9 mg RAY1225 administered subcutaneously (SC) once every two week.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"1 mg Semaglutide","ACTIVE_COMPARATOR","1 mg semaglutide administered SC once a week.",[23],"Drug: Semaglutide",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","RAY1225","Administered SC",[9,15],null,{"type":26,"name":32,"description":28,"armGroupLabels":33,"otherNames":30},"Semaglutide",[19],[35],{"name":36,"role":37,"phone":38,"phoneExt":30,"email":39},"Ji professor","CONTACT","88326666","iao@pkuph.edu.cn",[41],{"facility":42,"status":30,"city":43,"state":44,"zip":30,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Peking University People's Hospital","Beijing","Heibei","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":36,"role":37,"phone":30,"phoneExt":30,"email":30},{"type":56,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100603671","phase-3-a-study-of-ray1225-versus-semaglutide-as-add-on-therapy-to-oral-antidiabetic-drugs-in-participants-with-type-2-diabetes-100603671",false,"NCT07139548","A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes","A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n1. Have been diagnosed with type 2 diabetes mellitus (T2DM)\n2. Have HbA1c between ≥7.0% and ≤11.5%\n3. Have a body mass index (BMI) ≥20 kilograms per meter squared (kg\u002Fm²) at screening\n4. Be of stable weight (±5%) for at least 12 weeks before screening\n\nExclusion Criteria:\n\n1. Have type 1 diabetes mellitus\n2. Presence of severe chronic diabetic complications at screening, including but not limited to: proliferative diabetic retinopathy, diabetic macular edema, and severe non-proliferative diabetic retinopathy requiring acute treatment;\n3. History of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization;\n4. Occurrence of a Grade 3 hypoglycemic event within 12 months prior to screening, or ≥3 Grade 2 hypoglycemic events (venous or capillary blood glucose \\\u003C3.0 mmol\u002FL) within 3 months prior to screening, or presence of hypoglycemia-related symptoms ;\n5. History of severe trauma, severe infection, or surgery within 12 weeks prior to screening that may affect glycemic control;\n6. Receipt of blood transfusion within 12 weeks prior to screening, or blood donation\u002Floss ≥400 mL within 12 weeks prior to screening, or blood donation\u002Floss ≥200 mL within 4 weeks prior to screening, or known hemoglobinopathy (such as thalassemia, hemolytic anemia, sickle cell anemia, etc.);\n7. Any unstable or treatment-requiring endocrine disorders related to glycemic control other than type 2 diabetes mellitus (such as hyperthyroidism, acromegaly, Cushing's syndrome, etc.).","ALL","18 Years",{"count":67,"type":68},600,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.",[74],"T2DM","NOT_YET_RECRUITING","2025-08-17",{"date":78,"type":79},"2025-08-24","ACTUAL",{"date":81,"type":68},"2025-08-31",{"date":83,"type":68},"2026-12-31",{"name":5,"class":6},1]